Korbinian Weigl1, Hauke Thomsen2, Yesilda Balavarca3, Jacklyn N Hellwege4, Martha J Shrubsole5, Hermann Brenner6. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany; Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany. 2. Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany. 3. Division of Preventive Oncology, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, Germany. 4. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee. 6. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, Germany. Electronic address: h.brenner@dkfz-heidelberg.de.
Abstract
BACKGROUND & AIMS: The presence of specific single nucleotide polymorphisms (SNPs) can be used to calculate an individual's risk for colorectal cancer (CRC), called a genetic risk score (GRS). We investigated whether GRS can identify individuals with clinically relevant neoplasms in a screening colonoscopy population. METHODS: We derived a GRS based on 48 SNPs associated with CRC, identified in a comprehensive literature search. We obtained genetic data from 1043 participants (50-79 years old) in a screening colonoscopy study in Germany, recruited from 2005 through 2013 (294 with advanced neoplasms, 249 with non-advanced adenoma (NAAs), and 500 without neoplasms). Each participant was assigned a GRS by aggregating their risk alleles (0, 1, or 2). Risk of advanced neoplasms and NAA according to GRS was calculated by multiple logistic regression. Risk advancement periods were calculated. We replicated our findings using data from a subset of the Tennessee Colorectal Polyp Study. RESULTS: An increased GRS was associated with higher prevalence of advanced neoplasms, but not NAAs. Participants in the middle and upper tertiles of GRS had a 2.2-fold and 2.7-fold increase in risk, respectively, of advanced neoplasms compared to those in the lower tertile. Adjusted odds ratios (ORs) were 1.09 (95% confidence interval [CI], 0.76-1.57) for NAA in the middle tertile and 1.05 (95% CI, 0.70-1.55) for NAA in the upper tertile. The ORs were largest for proximal advanced neoplasms for participants in the middle tertile (OR, 3.55; 95% CI 1.85-6.82) and the upper tertile (OR, 3.61; 95% CI 1.84-7.10). The risk advancement period for medium vs low GRS was 13.4 years (95% CI 4.8-22.0) and for high vs low GRS was 17.5 years (95% CI, 7.8-27.3). CONCLUSIONS: In a genetic analysis of participants in a CRC screening study in Germany, an increased GRS (based on CRC-associated SNPs) was associated with increased prevalence of advanced neoplasms. These findings might be used in defining risk-adapted screening ages.
BACKGROUND & AIMS: The presence of specific single nucleotide polymorphisms (SNPs) can be used to calculate an individual's risk for colorectal cancer (CRC), called a genetic risk score (GRS). We investigated whether GRS can identify individuals with clinically relevant neoplasms in a screening colonoscopy population. METHODS: We derived a GRS based on 48 SNPs associated with CRC, identified in a comprehensive literature search. We obtained genetic data from 1043 participants (50-79 years old) in a screening colonoscopy study in Germany, recruited from 2005 through 2013 (294 with advanced neoplasms, 249 with non-advanced adenoma (NAAs), and 500 without neoplasms). Each participant was assigned a GRS by aggregating their risk alleles (0, 1, or 2). Risk of advanced neoplasms and NAA according to GRS was calculated by multiple logistic regression. Risk advancement periods were calculated. We replicated our findings using data from a subset of the Tennessee Colorectal Polyp Study. RESULTS: An increased GRS was associated with higher prevalence of advanced neoplasms, but not NAAs. Participants in the middle and upper tertiles of GRS had a 2.2-fold and 2.7-fold increase in risk, respectively, of advanced neoplasms compared to those in the lower tertile. Adjusted odds ratios (ORs) were 1.09 (95% confidence interval [CI], 0.76-1.57) for NAA in the middle tertile and 1.05 (95% CI, 0.70-1.55) for NAA in the upper tertile. The ORs were largest for proximal advanced neoplasms for participants in the middle tertile (OR, 3.55; 95% CI 1.85-6.82) and the upper tertile (OR, 3.61; 95% CI 1.84-7.10). The risk advancement period for medium vs low GRS was 13.4 years (95% CI 4.8-22.0) and for high vs low GRS was 17.5 years (95% CI, 7.8-27.3). CONCLUSIONS: In a genetic analysis of participants in a CRC screening study in Germany, an increased GRS (based on CRC-associated SNPs) was associated with increased prevalence of advanced neoplasms. These findings might be used in defining risk-adapted screening ages.
Authors: Li Hsu; Jihyoun Jeon; Hermann Brenner; Stephen B Gruber; Robert E Schoen; Sonja I Berndt; Andrew T Chan; Jenny Chang-Claude; Mengmeng Du; Jian Gong; Tabitha A Harrison; Richard B Hayes; Michael Hoffmeister; Carolyn M Hutter; Yi Lin; Reiko Nishihara; Shuji Ogino; Ross L Prentice; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Duncan C Thomas; Mark Thornquist; Polly A Newcomb; John D Potter; Yingye Zheng; Emily White; Ulrike Peters Journal: Gastroenterology Date: 2015-02-13 Impact factor: 22.682
Authors: Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2010-08-26 Impact factor: 13.491
Authors: Andrea N Burnett-Hartman; Polly A Newcomb; Carolyn M Hutter; Ulrike Peters; Michael N Passarelli; Malaika R Schwartz; Melissa P Upton; Lee-Ching Zhu; John D Potter; Karen W Makar Journal: Am J Epidemiol Date: 2014-05-29 Impact factor: 4.897
Authors: Emma Jaeger; Emily Webb; Kimberley Howarth; Luis Carvajal-Carmona; Andrew Rowan; Peter Broderick; Axel Walther; Sarah Spain; Alan Pittman; Zoe Kemp; Kate Sullivan; Karl Heinimann; Steven Lubbe; Enric Domingo; Ella Barclay; Lynn Martin; Maggie Gorman; Ian Chandler; Jayaram Vijayakrishnan; Wendy Wood; Elli Papaemmanuil; Steven Penegar; Mobshra Qureshi; Susan Farrington; Albert Tenesa; Jean-Baptiste Cazier; David Kerr; Richard Gray; Julian Peto; Malcolm Dunlop; Harry Campbell; Huw Thomas; Richard Houlston; Ian Tomlinson Journal: Nat Genet Date: 2007-12-16 Impact factor: 38.330
Authors: Ian P M Tomlinson; Luis G Carvajal-Carmona; Sara E Dobbins; Albert Tenesa; Angela M Jones; Kimberley Howarth; Claire Palles; Peter Broderick; Emma E M Jaeger; Susan Farrington; Annabelle Lewis; James G D Prendergast; Alan M Pittman; Evropi Theodoratou; Bianca Olver; Marion Walker; Steven Penegar; Ella Barclay; Nicola Whiffin; Lynn Martin; Stephane Ballereau; Amy Lloyd; Maggie Gorman; Steven Lubbe; Bryan Howie; Jonathan Marchini; Clara Ruiz-Ponte; Ceres Fernandez-Rozadilla; Antoni Castells; Angel Carracedo; Sergi Castellvi-Bel; David Duggan; David Conti; Jean-Baptiste Cazier; Harry Campbell; Oliver Sieber; Lara Lipton; Peter Gibbs; Nicholas G Martin; Grant W Montgomery; Joanne Young; Paul N Baird; Steven Gallinger; Polly Newcomb; John Hopper; Mark A Jenkins; Lauri A Aaltonen; David J Kerr; Jeremy Cheadle; Paul Pharoah; Graham Casey; Richard S Houlston; Malcolm G Dunlop Journal: PLoS Genet Date: 2011-06-02 Impact factor: 5.917
Authors: M J E Frampton; P Law; K Litchfield; E J Morris; D Kerr; C Turnbull; I P Tomlinson; R S Houlston Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: Catherine L Saunders; Britt Kilian; Deborah J Thompson; Luke J McGeoch; Simon J Griffin; Antonis C Antoniou; Jon D Emery; Fiona M Walter; Joe Dennis; Xin Yang; Juliet A Usher-Smith Journal: Cancer Prev Res (Phila) Date: 2020-02-18
Authors: Luke McGeoch; Catherine L Saunders; Simon J Griffin; Jon D Emery; Fiona M Walter; Deborah J Thompson; Antonis C Antoniou; Juliet A Usher-Smith Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-07-10 Impact factor: 4.254
Authors: Mark A Jenkins; Polly A Newcomb; Yingye Zheng; Xinwei Hua; Aung K Win; Robert J MacInnis; Steven Gallinger; Loic Le Marchand; Noralane M Lindor; John A Baron; John L Hopper; James G Dowty; Antonis C Antoniou; Jiayin Zheng Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-13 Impact factor: 4.254
Authors: Dong Hang; Amit D Joshi; Xiaosheng He; Andrew T Chan; Manol Jovani; Manish K Gala; Shuji Ogino; Peter Kraft; Constance Turman; Ulrike Peters; Stephanie A Bien; Yi Lin; Zhibin Hu; Hongbing Shen; Kana Wu; Edward L Giovannucci; Mingyang Song Journal: Int J Epidemiol Date: 2020-02-01 Impact factor: 7.196
Authors: Le Peng; Yesilda Balavarca; Korbinian Weigl; Michael Hoffmeister; Hermann Brenner Journal: Am J Gastroenterol Date: 2019-09 Impact factor: 10.864
Authors: Minta Thomas; Lori C Sakoda; Michael Hoffmeister; Elisabeth A Rosenthal; Jeffrey K Lee; Franzel J B van Duijnhoven; Elizabeth A Platz; Anna H Wu; Christopher H Dampier; Albert de la Chapelle; Alicja Wolk; Amit D Joshi; Andrea Burnett-Hartman; Andrea Gsur; Annika Lindblom; Antoni Castells; Aung Ko Win; Bahram Namjou; Bethany Van Guelpen; Catherine M Tangen; Qianchuan He; Christopher I Li; Clemens Schafmayer; Corinne E Joshu; Cornelia M Ulrich; D Timothy Bishop; Daniel D Buchanan; Daniel Schaid; David A Drew; David C Muller; David Duggan; David R Crosslin; Demetrius Albanes; Edward L Giovannucci; Eric Larson; Flora Qu; Frank Mentch; Graham G Giles; Hakon Hakonarson; Heather Hampel; Ian B Stanaway; Jane C Figueiredo; Jeroen R Huyghe; Jessica Minnier; Jenny Chang-Claude; Jochen Hampe; John B Harley; Kala Visvanathan; Keith R Curtis; Kenneth Offit; Li Li; Loic Le Marchand; Ludmila Vodickova; Marc J Gunter; Mark A Jenkins; Martha L Slattery; Mathieu Lemire; Michael O Woods; Mingyang Song; Neil Murphy; Noralane M Lindor; Ozan Dikilitas; Paul D P Pharoah; Peter T Campbell; Polly A Newcomb; Roger L Milne; Robert J MacInnis; Sergi Castellví-Bel; Shuji Ogino; Sonja I Berndt; Stéphane Bézieau; Stephen N Thibodeau; Steven J Gallinger; Syed H Zaidi; Tabitha A Harrison; Temitope O Keku; Thomas J Hudson; Veronika Vymetalkova; Victor Moreno; Vicente Martín; Volker Arndt; Wei-Qi Wei; Wendy Chung; Yu-Ru Su; Richard B Hayes; Emily White; Pavel Vodicka; Graham Casey; Stephen B Gruber; Robert E Schoen; Andrew T Chan; John D Potter; Hermann Brenner; Gail P Jarvik; Douglas A Corley; Ulrike Peters; Li Hsu Journal: Am J Hum Genet Date: 2020-08-05 Impact factor: 11.025